1249 GMT - Novo Nordisk has had a constructive first quarter on many fronts, but Barclays lowers its forecasts heading into the earnings report on lower Wegovy and Ozempic volumes in the U.S. than it previously forecast. Novo Nordisk has come off the FDA drugs shortage list and introduced its NovoCare direct-to-patient pharmacy efforts. But prescriptions didn't grow to the extent the bank needed them to in order to meet its forecasts. The bank now expects group sales growth this year at 19% at constant exchange rates, below the midpoint of company guidance at 16%-24%. A guidance cut at the first-quarter earnings report is "certainly possible, although Barclays continues to believe in the long-term story. Shares fall 2.3%. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 31, 2025 08:49 ET (12:49 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.